Thus, mucosal vaccination with the Env and Tat protein combination leads to an effective containment of viral infection at the portal of entry, with block of virus dissemination to lymph nodes following a very high rectal challenge dose. The gene discussed is ERVW-1; the disease is viral infectious disease.